ffi

l-

tffi\
I
-4'->'

t\rgrl I
lcm?
ffi \67
i]."1flt[??!E1,"3[

(-s+{ Eqa qrrfu 3Trgftsrr{ sr$iqri cRrq

ffiFt (sr.)qfi{rc qpfe, q-aq * wr*a r5sun F+mr
(,rg1. g\q. \s.j{rr$fr @.), qcsrr6t t{.). \s\'frfi, ersGqRqnoarq {zroq
(sc!qc. cslg'(rfl. qst.{qqfl, !sq\rs6. qs.vr.r.. a.('(.s. rTr{f, (T6R
gfua, qr{n ((6r{ ff <rqfirrerft r+r. siqrft T.n
FrR4 3r3qsrr frqrq
cR-qR 6flM 4rrfrq G
wrea gs
r{ffi- rro ozs
qaAkrcn', s{r$ S sc arm lndian Council of Medical Research
Oepartment of Health Research
Prof. (Dr,) Balram Bhargava, padmashri
Ministry of Heatth & Family Welfare
MO, DM, FRCP (Ghso.), FRCP (Edln.), Govemment of lndia
FACC. FAHA FAI.IS. FNASC, FASC, FNA, DSC
V Ramalingaswami Bhawan, Ansari Nagar
Secretary to the Goyernment ot lndia New Delhi - 110 029
D€parlm€nt ol H€atih Research
Ministry ol Health & Fsmily wo[are &
Director€ensral, ICMR O.O.No. EC D/COVID'l 9/M isc./2020
2nd July , 2o2o

Dear Colleagues (As per list attached),

Greetings from the lndian Council of Medical Research (ICMR)!

This is to bring to your kind attention that ICMR has partnered with Bharat Biotech lnternational Limited
(BBIL) to fast-track clinical trials of the indiSenous CoVID-19 vaccine (BBV152 COVID Vaccine).

This is the first indigenous vaccine being developed by lndia and is one of the top Priority prolects which
is being monitored at the topmost level of the Government. The vaccine is derived from a strain of SARS-
CoV-z isolated by tCMR-National lnstitute of Virology, Pune. ICMR and BBIL are jointly working for the
preclinical as well as clinical development of this vaccine.

It is envisaged to launch the vaccine for public health use latest by 15thAugust2020 after completion of all
clinical trials. BBIL is working expeditiously to meet the target, however finaloutcome will depend on the
cooperation of all clinical trial sites involved in this pro.iect.

you have been chosen as a clinical trial site of the BBV152 COVID vaccine. ln view of the public health
emergency due to COVID-19 pandemic and urgency to launch the vaccine, you are strictly advised to fast
track all approvals related to initiation of the clinical trial and ensure that the subiect enrollment is
initiated no later than 7th July 2020.

Kindly note that non-compliance will be viewed very seriously. Therefore, you are advised to treat this
project on highest priority and meet the given timelines without any lapse.

With regards

Yours sincerely

er//44L D&eryr- (Balram Bhargava)

Copy to:

1.Dr. Krishna Ella, CMD, Bhart Biotech, Hyderabad, AP

2.0r. Krishna Mohan, Sr.Vice-President, Bharat Biotech, Hyderabad, AP
Tele.: 26588204, 26589620, Fax (Off.):91-'l l-26588662' E-mail: secy{g@icmr.gov in
 avFo FZ9TI 2.>oo FC:9UU
I
>x-lol z I

ZF< 3 <3 r"l {OqAS P =z lDdt> J@ ra !)l

q= l

:!
ga r x-7 :?r!-= x-= L/ o =B -l
t1
t 7o 6
s.=
P-I o) ai @'- -; I
(D'id
=>'e ,9A !- iBEiI
^c
o;: 5 rlo e q)
_:
o ro i'')
*qt *Fl
oi o- *.
a-=2-
;'d =9
<'==- s^ a'a (!
I= /J 2-]I, J Z

IP
=-
nio=
ar.) D) ts"f ; =y
=c) =
E)
o
aD O-1^ T a7 t:-
oo- oe -)p o =.o ='
AF = l< =
oa
o
, I=
-rax
tdo
I
e< ^ lo)
t=
o kro Y. -' l!e
I 'Et
o- lPgo < I

I
^i- I lF)
lo l0
I

I
I

lo- la- lo- o-

l='
to tx'
l= 0c EI -
1> la) 0: h L='
AE = l= lo ll1i 1..
l5 lc lo la hr
:t(D lo 1
l(! r^\
lo l=
br
l:1

lrD
6le. E
lrr
t=
l(D

{r,l
t- t? tE Itz t=:
t..t= a li ,II,, la-
la l; {a lE
l3 E' to- 0'.
la) lo-
lo- l:. (o = lc (F)
la lii lo t:.
l- Ua
li. t:- E 3 lb a t3
l.) l=' l= k le.
lq l- lo IJ t-
ls) t lr- l3 li)
i' lo

T=AA z>=o (DA:r >AUtr

>o a :OF'Etr !>z-! FC!U3U
oJ:
z
6'6 7e.> :7!R o tOa2,J
f-N O O r
Aa
E z= EP
3 < ar T?
!r (!:--oE X"
==.D:rE x
i; ra +oa B) ! o
7:1 \)= 0 < - ^1'
.=<0n I tr ='+
@
'- liaA'
='i a
=.$ -z .2U)g-F, o8 i i
rEa
D:-r-a+ =
-Et ^a v
== C'
E { a E',n
=>.dz
,.d 47 --i Qrd
(! h'o o =- R f o
- f.a6='
.i e F€(,! S ''E =0a =B.oE (!P
i .3 5 ;.{ ; \o
}Q ? 6 z
=-=A)
o
39Y9S N=l r
\o dE J rD *xd
!/
= 9a> a
='o;O+=oa?
f?.cpzEJ' a <'* =.d
'i'rE
^S=
IDQ - =' 9.4 9 <z\ (!
^=.
m:i H>"-t P3 =^
-;
oU I E 3,r
.!=
q9 q- E
II 4;'E
A,=A T
z d!"i 9. l=' Il3c Bli y
o-- -' - 6- : l6
o- -z
AJE o
6-

lo to- lo- l5
lo
l= l:r
la)
ta
lrD

tf lo-
l!0 llo. IC'
l= la')
k IT ls
=
lo)
0a
ts l--
q1
E (e) ha
l=' l!J
to
IL {R)
to
Ua l= t-
l*J
l-_ l.!. h._
l= Ur
t! ti* L-r 1l li! t?.
(s) ls t- lP.
L; lo- q9 Itr lh t-
lo lq {o t= lo A
lo) E l!D
lo
It lb lF) lb
l3
lo l= b.
c)<zioO(, 3aT9 aaF alvl
o O:r -)Oao
EiFJ g;C (,
r" =r=o .D \of ==
TE xE'
6
o o a-
I ?2 z1
: _ai
(IO
(n E -, O)
9>H =
+ -:iD=
!! =oa -*. ci > EZa zt
O:5B
3\-)' 6
=0aE \<poPI= PL<B ES o 6'
o) O ' 0) iii a-r\ <l o a
u,:i
--'\
.j *P.L' 'z1 =_
ooi -/\=
Y.p d o
'- -!. ,j, 'i- fi s_9
0a s
g{ : K = -9 ro
!D
ii99 i" 6-
rc) a\o t-.i 0a
+< iS 'on
o- '- ;r H.E ^., = :E
o
f(J
a+
'-
t c,a7 .Y
; =\, 2:
!.
et
D)
lto
c
?i;
' t-)
F
(D a

to- l:- lO- to- l6-

l., l:r t-.
la l3 te
fio
lo
llo to
l=
l2 (_o
t; lc t,;
lo-
l=- lo
It lh
["=) lDi lx lo-
0c l:. tc
t.-.
t3
lP. R
l- tr3,
ta
t3 l3

,E .tr' C/' UI IDEU 7,FAA

9Fd'Y
Bi97o
b)
'! iE
AE<E
(i

oal dJ
F) X -, =oq
E t, Pa= P-'-. ==.>
E + tlJ
c =an I
I:68
p o
E
a V-
oE >
'n :1 x P- ()
--1 na= tu <=> i =.4
99
o9.P 2>V = o;
ia
q9. tA'--
^-= 0a gqc P i!;m Ig a=c)
a= 6i! < _2. x ,EI
36 :'+
=
L5 P o=v cs <%
3
B
i-= Ery nZ+o
o(J 7 oo Pc,;-
3
'o ga iu: a oq
e:- jr
6
oa R'2 its
qs' 6'
5 r'a
t+
m

lo- r= lo- l< b

lk ij-. l=
oi lE
l-
llD tl
l2 ts
l.i t)
t<
{s)
Ua
o_ lo L=
l6- {o l6
l=
la lo
{a)
tr
3
6
E
IP
l!o
lo
l3
11. IJ t-.
t- l=
lo
l= lo